Get the Stockscreener App
1.65
3.77%
0.06
Ensysce Biosciences Inc stock is traded at $1.65, with a volume of 51,271.
It is up +3.77% in the last 24 hours and down -20.67% over the past month.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
See More
Previous Close:
$1.59
Open:
$1.62
24h Volume:
51,271
Relative Volume:
0.48
Market Cap:
$5.99M
Revenue:
-
Net Income/Loss:
$-11.28M
P/E Ratio:
-0.5482
EPS:
-3.01
Net Cash Flow:
$-9.78M
1W Performance:
-6.78%
1M Performance:
-20.67%
6M Performance:
-30.67%
1Y Performance:
-78.25%
1-Day Range:
$1.52
$1.68
1-Week Range:
$1.46
$1.8499
52-Week Range:
$1.46
$10.96
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Name
Ensysce Biosciences Inc
Sector
Industry
Phone
(858) 263-4196
Address
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
1.65 | 5.78M | 0 | -11.28M | -9.78M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ensysce Biosciences Inc Stock (ENSC) Latest News
How Ensysce Biosciences Inc. stock performs in interest rate cyclesQuarterly Profit Review & Real-Time Buy Signal Notifications - Newser
Why Ensysce Biosciences Inc. stock attracts high net worth investorsIPO Watch & Free Weekly Chart Analysis and Trade Guides - Newser
Ensysce (NASDAQ: ENSC) secures MPAR overdose tech patent protection to 2042 - Stock Titan
Is Ensysce Biosciences Inc. stock near bottom after declineEarnings Beat & Weekly High Conviction Trade Ideas - Newser
Will Ensysce Biosciences Inc. stock outperform international peersProfit Target & Verified Stock Trade Ideas - Newser
Earnings Beat: Why Ensysce Biosciences Inc. stock is seen as undervalued2025 Volatility Report & Fast Gaining Stock Reports - BỘ NỘI VỤ
Ensysce Biosciences Inc. (ENSC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Ensysce Biosciences, Inc.Common Stock (NQ: ENSC - Markets Financial Content
[PRE 14A] Ensysce Biosciences, Inc. Preliminary Proxy Statement - Stock Titan
Will Ensysce Biosciences Inc. stock benefit from AI adoption2025 Volatility Report & Community Shared Stock Ideas - newser.com
Ensysce Biosciences’ Innovative Approach to Safer Opioid Use: A Clinical Study Update - MSN
Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach - The Joplin Globe
Ensysce (NASDAQ: ENSC) Receives FDA Agreement on PF614 Commercial Manufacturing Approach - Stock Titan
Why Ensysce Biosciences Inc. stock is popular among millennialsJuly 2025 Outlook & Growth Oriented Trade Recommendations - newser.com
FY2025 Earnings Estimate for ENSC Issued By Zacks Small Cap - Defense World
Real time social sentiment graph for Ensysce Biosciences Inc.New Guidance & Free Technical Pattern Based Buy Signals - newser.com
Is Ensysce Biosciences Inc. stock trading near support levelsTrade Exit Summary & Proven Capital Preservation Tips - newser.com
What the charts say about Ensysce Biosciences Inc. todayTrade Signal Summary & Weekly High Return Stock Forecasts - newser.com
How currency fluctuations impact Ensysce Biosciences Inc. stockWeekly Investment Recap & Technical Analysis for Trade Confirmation - newser.com
Momentum divergence signals in Ensysce Biosciences Inc. chart2025 Technical Overview & Expert Verified Stock Movement Alerts - newser.com
What catalysts could drive Ensysce Biosciences Inc. stock higherJuly 2025 Closing Moves & Weekly Top Gainers Alerts - newser.com
Ensysce Biosciences Secures $4M Financing for PF614 - The Globe and Mail
Will Ensysce Biosciences Inc. stock remain a Wall Street favorite2025 Year in Review & Short-Term Trading Opportunity Alerts - newser.com
[8-K] Ensysce Biosciences, Inc. Reports Material Event | ENSC SEC FilingForm 8-K - Stock Titan
Ensysce Biosciences : Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs - marketscreener.com
Ensysce Biosciences (NASDAQ: ENSC) closes $4M round, unlocking $16M for PF614 Phase 3 - Stock Titan
Ensysce Biosciences, Inc. announced that it has received $2.487 million in funding - MarketScreener
How high can Ensysce Biosciences Inc. stock goProduct Launch & Fast Exit/Entry Strategy Plans - newser.com
Why retail investors pile into Ensysce Biosciences Inc. stockJuly 2025 Weekly Recap & Trade Opportunity Analysis - newser.com
Ensysce Biosciences Reports Increased R&D Expenses Amid Net Loss - TipRanks
Ensysce Biosciences reports Q3 net loss - MarketScreener
Ensysce Biosciences (NASDAQ: ENSC) begins Phase 3 PF614 trial; Q3 net loss $3.7M - Stock Titan
Ensysce Biosciences Inc Stock (ENSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):